Genetic Engineering in Diabetes: Recombinant Insulin, Gene Therapy, and Xenotransplantation
Genetic engineering has revolutionized diabetes care and holds future promise.
Current Applications
- Recombinant human insulin: Produced in E. coli or yeast since 1982; identical to human insulin; replaced animal insulins.
- Insulin analogs: Engineered amino acid substitutions → rapid-acting (lispro, aspart, glulisine) or long-acting (glargine, detemir, degludec) profiles.
- Advanced delivery: Insulin pumps, closed-loop “artificial pancreas” systems using CGM algorithms.
Emerging Therapies
- Gene therapy: Viral (AAV) or non-viral delivery of insulin/transcription factors to hepatocytes or pancreatic progenitors to restore endogenous production.
- Cell replacement: Stem cell-derived beta cells (e.g., Vertex VX-880) encapsulated or gene-edited for immune evasion.
- Xenotransplantation: CRISPR-edited pig islets (knockout of GGTA1, CMAH, β4Gal, + human transgenes) for unlimited supply.
- Disease modeling: iPSCs from patients with monogenic diabetes (MODY, neonatal) for drug screening.
- Personalized medicine: Pharmacogenomics (e.g., TCF7L2, KCNJ11) guiding sulfonylurea vs. insulin choice.
Most are in clinical trials; recombinant insulin/analogs are standard of care today.
Genetic Disorders - Related Articles
- Hearing Aids for Down Syndrome: Understanding Hearing Loss & Options
- Understanding and Diagnosing Color Blindness: A Comprehensive Guide
- Agent Orange Exposure and Birth Defects: Understanding the Risks
- Rapunzel Syndrome (Trichobezoar): Causes, Presentation & Management
- Congenital Chloride Diarrhea (CLD) Support & Resources
- Genetic Factors in Cardiovascular Disease: Understanding Your Risk
- Congenital: Present from Birth – Causes & Examples
